Type
Buy
Instrument
JMFINANCIL
Entry Price
₹90.8
Price@Trade
₹90.85
Target Price
₹92.5
Stop Price
₹86
Valid Till
Sep 20, 2021 3:20 AM
Margin
₹45,400 approx for 500 Qty
Status
Waiting for entry
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
- Home
- JMFINANCIL Forum
JMFINANCIL
93.15 +0.15 (0.16%)
Updated 12:52 28/09 IST
100% Bullish
0% Bearish
3 Users have submitted 3 trade ideas of Rs. 147,026.5 for JMFINANCIL
DisclaimerBrokerage Reports
No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
JMFINANCIL Share Price Discussion
N
Reputation: 17,842 • Sep 17 11:26 AM
JM Financial to raise Rs 500 crore via public bond sales
Local rating companies – ICRA and CRISIL rated those papers with AA (Stable outlook). Bonds will offer up to 8.30 percent. Maturities are spread across 39 months to 100 months.
Local rating companies – ICRA and CRISIL rated those papers with AA (Stable outlook). Bonds will offer up to 8.30 percent. Maturities are spread across 39 months to 100 months.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Sep 16 5:26 AM
JM Financial's subsidiary to raise up to Rs 500 crore
"JM Financial Products has filed the shelf prospectus and tranche I prospectus with the Registrar of Companies, Mumbai and the Sebi," JM Financial said in a regulatory filing.
"JM Financial Products has filed the shelf prospectus and tranche I prospectus with the Registrar of Companies, Mumbai and the Sebi," JM Financial said in a regulatory filing.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Sep 16 3:31 AM
Buy JM Financial, target price Rs 96: HDFC Securities
JM Financial Ltd. key Products/Revenue Segments include Fees & Commission Income, Income From Financial Services and Interest for the year ending 31-Mar-2021.
JM Financial Ltd. key Products/Revenue Segments include Fees & Commission Income, Income From Financial Services and Interest for the year ending 31-Mar-2021.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Sep 14 8:06 AM
After a 30% rally, can HUL rerate further? Here is what analysts say
Given the scope of premiumisation in product categories, cost-saving initiatives, focus on acquiring digital capabilities and the management commentary on double-digit growth in earnings, most brokerages said the stock could rise up to 20 per cent over the next 12 months.
Given the scope of premiumisation in product categories, cost-saving initiatives, focus on acquiring digital capabilities and the management commentary on double-digit growth in earnings, most brokerages said the stock could rise up to 20 per cent over the next 12 months.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Sep 13 4:56 AM
What's next for Nifty? 2009, 2003 market cycles offer clues
History suggests Indias 125 per cent re-rating-driven rally from March 2020 lows was similar to early market cycles of 2003 (Nifty up 91 per cent) and 2009 (Nifty up 138 per cent) where the market delivered outsized returns from depressed levels, thanks to low cost of capital.
History suggests Indias 125 per cent re-rating-driven rally from March 2020 lows was similar to early market cycles of 2003 (Nifty up 91 per cent) and 2009 (Nifty up 138 per cent) where the market delivered outsized returns from depressed levels, thanks to low cost of capital.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Aug 31 6:56 AM
Will Burger King India's entry into 4th most populated country make it a tastier bet?
Analysts said there were growth prospects in Indonesia and the acquisition was attractive value-wise. The deal could increase the fair value of Burger King India by Rs 25 apiece, they said. But for now, they have kept the price targets unchanged.
Analysts said there were growth prospects in Indonesia and the acquisition was attractive value-wise. The deal could increase the fair value of Burger King India by Rs 25 apiece, they said. But for now, they have kept the price targets unchanged.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Aug 20 12:11 PM
Emcure Pharma files DRHP for IPO
Pune-based Emcure Pharmaceuticals, one of Indias biggest unlisted pharma companies, filed its draft red herring prospectus (DRHP) with the market regulator Sebi on Thursday to raise money through an initial public offer.
Pune-based Emcure Pharmaceuticals, one of Indias biggest unlisted pharma companies, filed its draft red herring prospectus (DRHP) with the market regulator Sebi on Thursday to raise money through an initial public offer.
The Economic Times
Like
Reply
N
Reputation: 17,842 • Aug 19 9:31 AM
Emcure Pharma files draft paper for Rs 5,000 cr IPO
Emcure claims to be an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine, which has enabled it to reach a range of target markets across over 70 countries with a strong presence in Europe and Canada.
Emcure claims to be an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine, which has enabled it to reach a range of target markets across over 70 countries with a strong presence in Europe and Canada.
The Economic Times
Like
Reply
JMFINANCIL Ratings
Long term JMFINANCIL rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
0/5 (0 Ratings)0
Find answers to all your questions on live JMFINANCIL message board: Is JMFINANCIL buy or sell? Should I buy JMFINANCIL shares? Why are JMFINANCIL shares falling? Should I invest in JMFINANCIL stock?
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
JMFINANCIL Share Price - Technicals
- NewsBotJust now
Buy JM Financial, target price Rs 99: HDFC SecuritiesThe Economic TimesNewsBotSep 16 5:26 AMJM Financial's subsidiary to raise up to Rs 500 croreThe Economic TimesNewsBotSep 16 3:31 AMBuy JM Financial, target price Rs 96: HDFC SecuritiesThe Economic TimesNewsBotAug 31 6:56 AMWill Burger King India's entry into 4th most populated country make it a tastier bet?The Economic TimesNewsBotAug 20 12:11 PMEmcure Pharma files DRHP for IPOThe Economic TimesNewsBotAug 19 9:31 AMEmcure Pharma files draft paper for Rs 5,000 cr IPOThe Economic TimesNewsBotAug 19 6:46 AM
Emcure Pharma files draft paper for Rs 4,000 cr IPOThe Economic TimesNewsBotAug 17 4:36 AM
IDBI Trusteeship approaches NCLT against Noida developer Shipra EstateThe Economic TimesNewsBotAug 13 3:21 AM
Govt-backed IFCI slips to high-yield grade, raises investor concernThe Economic TimesNewsBotAug 12 12:11 PM
Aditya Birla AMC likely to launch IPO in SeptemberThe Economic Times
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.